The U.S. Food and Drug Administration has granted approval for application ANDA080256 submitted by Eli Lilly and Company. The approval covers two methyltestosterone tablet products intended for buccal and sublingual administration, containing 10 mg and 25 mg of the active ingredient respectively.
Both products are listed with a marketing status of "Discontinued." The original submission (type ORIG) received an approval status (AP) on December 22, 1971.
規制動向2026年8月30日•1分で読めます
FDA Approves Lilly Methyltestosterone Tablet ANDA080256 (Discontinued)
FDA approved Lilly's ANDA080256 for methyltestosterone tablets (10 mg and 25 mg) buccal/sublingual on Dec 22 1971; both products are now discontinued.
PharmaCountryチームがまとめました · 出典： FDA.gov
評価
(0)
(0)
(0)
(0)
(0)
評価を残す